Remission of idiopathic retroperitoneal fibrosis by ofatumumab as a disease-modifying therapy for multiple sclerosis
eNeurologicalSci
.
2022 Sep 27:29:100428.
doi: 10.1016/j.ensci.2022.100428.
eCollection 2022 Dec.
Authors
Akira Hanazono
1
,
Yui Sanpei
1
,
Hinako Shimada
1
,
Keita Yasuda
1
,
Yoshiko Takahashi
1
,
Homare Funasaka
1
,
Ryuichiro Sagehashi
2
,
Yuko Hiroshima
3
,
Hiroshi Nanjo
3
,
Masashiro Sugawara
1
Affiliations
1
Akita University Graduate School of Medicine, Department of Neurology, Japan.
2
Akita University Graduate School of Medicine, Department of Urology, Japan.
3
Akita University Hospital, Division of Clinical Pathology, Japan.
PMID:
36193452
PMCID:
PMC9526141
DOI:
10.1016/j.ensci.2022.100428
No abstract available
Keywords:
Dimethyl fumarate; IgG4-related disease; Interferon β1b; Rituximab.